Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Philips says U.S. deal will enable it to ramp up ventilator production

Published 04/08/2020, 05:11 PM
Updated 04/08/2020, 05:20 PM
© Reuters. FILE PHOTO: Dutch health technology company Philips presents the company's financial results for the fourth quarter in Amsterdam

AMSTERDAM (Reuters) - Dutch health technology company Philips (AS:PHG) said on Wednesday it struck a deal with the White House that will enable it to significantly ramp up its production of hospital ventilators as promised.

Philips said it would deliver the U.S. government 43,000 hospital ventilators, an essential tool for the treatment of patients struggling with the novel coronavirus disease COVID-19, throughout the rest of the year for a total sum of $647 million.

As part of the deal, President Donald Trump has ordered suppliers to prioritise their shipments to the two U.S. factories where Philips produces its ventilators, Chief Executive Frans van Houten told Reuters.

Philips will be allowed to continue its shipments of ventilators to the rest of the world, where the appliances are also in high demand.

"This helps", Van Houten said in a reference to Trump's use of the Defense Production Act (DPA), a law dating back to the Korean War of the 1950s that grants the U.S. president sweeping authority to expedite and expand the supply of resources from U.S. factories.

"We came to a good solution and now we can focus on further increasing production", Van Houten said.

Philips earlier warned that protectionist measures such as the DPA could jeopardise its promise to rapidly increase production of critical medical supplies for the diagnosis and care of coronavirus patients.

The company said last month it would ramp up production of hospital ventilators to 4,000 a week by the third quarter, after having doubled it to 1,000 units per week in March.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.